Soleymani Majd Hooman, Ismail Lamiese, Hardern Kieran, Ferrari Federico, Kehoe Sean
a Department of Gynaecological Oncology , Churchill Hospital , Headington , Oxford , UK.
b Department of Obstetrics & Gynaecology , John Radcliffe Hospital , Oxford , UK.
J Obstet Gynaecol. 2017 Jan;37(1):89-92. doi: 10.1080/01443615.2016.1225029. Epub 2016 Dec 15.
This study examines the overall survival of primary peritoneal cancer (PPC), in those patients who had primary debulking surgery (PDS) followed by six cycles of chemotherapy versus those who had neoadjuvant chemotherapy (NACT). This was a prospective observational study performed at Oxford Gynaecological Cancer Centre, over a 5-year period. Eighty-seven patients were clinically suspected of having PPC. Histology confirmed that 64 of these were PPC, with the balance being tubal in origin. PDS was performed in 31 cases. Although NACT was planned in 56 patients, 4 patients didn't receive NACT and therefore excluded from the survival analysis. The overall median survival was 34 months. However, the 5-year survival was 12%. Survival in the PDS group was 46 months versus 24 months in the NACT (p = .011). The conclusion drawn from this study is that patients affected by PPC, selected for PDS have a greater survival advantage than those who had NACT.
本研究考察了接受初次肿瘤细胞减灭术（PDS）并进行六个周期化疗的原发性腹膜癌（PPC）患者与接受新辅助化疗（NACT）的患者的总生存期。这是一项在牛津妇科癌症中心进行的为期5年的前瞻性观察性研究。87例患者临床上疑似患有PPC。组织学检查证实其中64例为PPC，其余起源于输卵管。31例患者接受了PDS。虽然计划对56例患者进行NACT，但4例患者未接受NACT，因此被排除在生存分析之外。总中位生存期为34个月。然而，5年生存率为12%。PDS组的生存期为46个月，而NACT组为24个月（p = 0.011）。本研究得出的结论是，被选择接受PDS的PPC患者比接受NACT的患者具有更大的生存优势。
